[Guidelines for diagnosis and treatment of advanced breast cancer in China (2024 edition)].

Abstract

Breast cancer is the most common malignant tumor among women all over the world. In 2022, there were about 357,161 new cases and 74,986 deaths of breast cancer in Chinese female. Of the new cases of breast cancer each year, about 5% to 10% of patients have distant metastasis at the time of diagnosis. Of the early-stage patients, about 20%~30% developed into advanced breast cancer eventually. Although advanced breast cancer is difficult to cure at present, we can alleviate the clinical symptoms of patients, improve their quality of life and further prolong their survival time by applying new therapeutic drugs and optimizing treatment models, to achieve the purpose of long-term survival with tumor. To better guide clinical practice, the Chinese expert group, based on the latest research progress in breast cancer, has analyzed, discussed, and updated the relevant research data on the basis of "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2022 edition)" to form the "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2024 edition)" . The updated guideline incorporates the new evidence of high-quality evidence-based medicine, new concepts in molecular pathological detection, new treatment strategies, new progress in precision medicine, and adverse events of new therapeutic drugs. At the same time, the updated guideline emphasizes multidisciplinary collaboration and pays attention to patient-reported outcomes. The "Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2024 edition)" aims to provide clinicians with recommendations for the diagnosis and treatment of advanced breast cancer in China, thereby improving patient outcomes and quality of life.